The Relationship Between Anxiety and Alzheimer’s Disease 1

Abstract

Although Alzheimer’s disease (AD) is primarily a neurocognitive disorder, it also results in prominent neuropsychiatric symptoms (NPS). Much literature has investigated the NPS of apathy and depression in association with AD, but relatively less is known regarding anxiety, the third most common NPS in this disorder. The prevalence of anxiety symptoms in AD is about 40%, and it can be a prelude of AD. Anxiety can be especially present among patients with mild cognitive impairment, mild dementia, or early-onset forms of the disease, and can promote progression or conversion to Alzheimer’s clinical syndrome. A number of studies have established that anxiety is associated with positive amyloid scans, mesial temporal changes with atrophy and hypometabolism in the entorhinal region, and neurofibrillary tangles present on pathological examination of this region. In addition to psychosocial factors, proposed neurobiological mechanisms for increased anxiety in AD include decreased sensorimotor gating, relatively increased activation of amygdalae or the Salience Network, and the presence of comorbid pathology, particularly Lewy bodies. Having management strategies for anxiety in patients with AD is important as anxiety can worsen cognitive deficits. Interventions involve psychological support, behavioral management, and the judicious use of the psychiatric armamentarium of medications.

INTRODUCTION

Alzheimer’s disease (AD) is the leading cause of dementia, with a worldwide prevalence that continues to rise as populations age. Currently there are almost six million people in the U.S. with AD and many others experience mild cognitive impairment (MCI), which can be a prelude to the Alzheimer’s clinical syndrome [1, 2]. Recent advances in AD have targeted the identification of risk factors and biomarkers. Risk factors for the disorder include advanced age, hypertension, diabetes, smoking, obesity, depression, traumatic brain injury, air pollution, excessive alcohol consumption, hearing impairment, low education, and limited social contact [3]. Additional considerations are the presence of sleep disorders and genetic factor such as having one or more apolipoprotein E (APOE) ɛ4 allele. In addition, there have been significant advances in the clinical diagnosis of AD with cerebrospinal fluid (CSF) and new neuroimaging biomarkers for amyloid and tau [4]. Research and advances are particularly lacking for understanding the neuropsychiatric symptoms (NPS) of AD, especially the role of anxiety.

Most clinicians know AD as a disorder affecting declarative, episodic memory or new learning and other spheres of cognition. Indeed, the typical late onset AD appears as a progressive amnestic disorder with additional deficits in word-finding and language, spatial and visuoperceptual processing, and executive abilities [2]. About 5–6%of patients with AD have an early-onset (EOAD) before age 65 [5], and these patients include a high percentage of variants with predominant language or visuospatial impairments [5].

Regardless of age of onset, AD also results in signi-ficant non-cognitive neuropsychiatric symptoms (NPS) [6], including apathy, depression, anxiety, agitation, aggression, and psychosis [7]. Beyond apathy, depression and anxiety disorders are the most common NPS in AD [8], present in up to 75%of patients with AD [9]. The presence of depression and anxiety have important implications for the patients’ quality of life, caregiver well-being, and likelihood for hospitalizations, institutionalization, and overall mortality [7, 10]. This review focuses on what is known about the relationship of anxiety with AD.

METHODS

A systematic review of the literature was initiated by searching the following electronic databases: PubMed and Google-Scholar. The search consisted of the following terms: “dementia,” “Alzheimer’s disease,” “mild cognitive impairment,” AND “anxiety,” “nervousness,” “psychiatric,” “neuropsychiatric,” “behavior,” “behavioral.” The literature search began October 1, 1995 and concluded October 1, 2020, a span of 25 years. Inclusion criteria for this report were papers available in English and including the following: 1) the inclusion of patients with AD rather than dementia in general; and 2) the presence of anxiety or related words such “nervousness” or “neuroticism”. Using these criteria, the initial search of 237 publications yielded 75 studies for this review. The following discussion focuses on an interpretation of these studies, rather than a comprehensive review of each individual publication.

PREVALENCE OF ANXIETY IN AD

Among the NPS of AD, there have been many investigations of depression [11, 12], but relatively few on anxiety. Yet, the presence of anxiety significantly exacerbates the cognitive impairments of AD, making its early recognition and management particularly important [13]. The prevalence estimates for anxiety in dementia range from 5–21%for anxiety disorders without depression and from 8–90%for significant anxiety symptoms at some time in their course [14–17]. Anxiety may be particularly associated with AD [14, 18–21]. A meta-analysis of 48 studies using the Neuropsychiatric Inventory (NPI) reports a pooled prevalence estimate for anxiety in AD of 39%(95%CI 32–46%) [22]. Anxiety in AD tends to be generalized anxiety with no clear association with demographic factors such as sex, education, or ethnicity [18, 23].

ANXIETY AS A RISK FACTOR FOR AD

A number of recent studies have indicated that anxiety can be a risk factor for AD independent of the presence of depression [24, 25]. In a large longitudinal (4.5 year), community-based study of over four thousand dementia-free persons ≥55 years of age, there was a significant association between anxiety at baseline and eventual AD [25]. In another study of over twelve thousand cognitively asymptomatic participants, anxiety, along with depression and sleep disturbance, independently and as a comorbid factor, was associated with the development of AD [26]. In a third cross-sectional study of 1,417 older adults the majority of whom were cognitively normal, the number of comorbid NPS, including anxiety, was associated with a threefold increased risk of dementia and a twofold increased risk of MCI [27]. Finally, in a large study and meta-analysis of personality studies, participants with high scores on neuroticism, a construct that includes anxiety, and low conscientiousness, showed a threefold increased risk of developing AD on follow-up [28].

ANXIETY AS AN INITIAL OR PRODROMAL SYMPTOM OF AD

Anxiety may be an early manifestation of AD, even heralding the initial stages of cognitive decline [9, 29–35]. Anxiety is particularly present among those with MCI or mild dementia, compared to those with more advanced dementia, especially if they have retained insight into their condition [14, 36–38]. Multiple studies indicate that the presence of anxiety can increase the rate for conversion from MCI to dementia [39–42]. Indeed, longitudinal studies of non-demented patients with positive amyloid scans report that elevated anxiety levels are associated with a more rapid decline, particularly in memory [43–45]. In a comparison of 104 cognitively unimpaired and 53 MCI patients followed for up to 4 years who had anxiety on the Hospital Anxiety and Depression Scale, anxiety was related to amyloid-β (Aβ) deposition on flutemetamol amyloid positron emission tomography (PET) imaging [45]. In this study, the presence of anxiety also predicted cognitive decline and interacted with amyloid status to predict faster cognitive deterioration [45]. But the presence of anxiety among mild AD patients followed for up to 5 years may not predict progression as well as other NPS symptoms on the NPI, such as delusions, agitation, and aberrant motor behavior [46]. Nevertheless, the occurrence of anxiety appears most associated with early AD.

Initial or prodromal anxiety may be most prominent among patients with the early-onset forms of AD that begin at < 65 years of age (EOAD) [14, 48]. EOAD differs from the usual late onset disorder in its high prevalence of nonamnestic phenotypic variants that spare the hippocampi but have greater tau burden in posterior neocortices. In a comparison of 23 EOAD and 22 late-onset AD (LOAD) patients, significantly more EOAD patients reported anxiety on the NPI Anxiety subscale than the LOAD patients (70%versus 27%, respectively) [14]. In another NPI comparison of EOAD (n = 24) and LOAD (n = 56) participants with mild dementia, the EOAD patients had greater prevalence of all NPS except apathy, and they were significantly worse on anxiety (p = 0.03) as well as irritability (p = 0.01) and sleep (p < 0.01) subscales [49]. Others have found equal amounts of NPS on the NPI, including anxiety, among EOAD (n = 35) and LOAD (n = 35) patients [50]. In fact, LOAD patients do experience anxiety, but often as the dementia progresses and in association with comorbid psychiatric and behavioral symptoms [30, 52]. The anxiety in middle or late stages of AD may manifest as agitation and signs of emotional distress, with inappropriate or excessive vocal or motor activity.

ASSOCIATION WITH NEUROPATHOLOGY

Much of the literature has suggested that anxiety is due to AD neuropathology, rather than hippocampal damage due to anxiety-induced mechanisms, such as elevated cortisol levels [42]. Although MRI studies have not found an association between anxiety in AD and gray matter changes [53–55], some investigators have shown increased white matter hyperintensities associated with anxiety, suggesting a vascular component [56]. In another MRI study, the presence of anxiety was associated with greater rates of decrease in entorhinal cortex volume on regions of interest analysis [42]. On fluorodeoxyglucose PET imaging, when investigators controlled for cognitive decline, they showed higher anxiety correlates with lower metabolism in bilateral entorhinal cortex, bilateral anterior parahippocampal gyrus, left anterior superior temporal gyrus, and left insula [57]. After further controlling for other NPS, their results were still significant in the right entorhinal cortex and parahippocampal gyrus. An older study looking at regional cerebral blood flow additionally suggested decreased parietal hypometabolism [58]; however, they were not able to confirm this finding in a subsequent study [57]. In sum, anxiety may be associated with involvement of the mesial temporal lobe, particularly the entorhinal region [42, 59].

Several studies have shown an association of anxiety with biomarkers of AD pathology. Among patients with MCI or AD, there is a significant correlation between NPS and an increased CSF t-tau/Aβ₄₂ ratio, a biomarker of AD neuropathology [38]. A number of amyloid PET investigations report increased anxiety measures with positive amyloid PET imaging and faster cognitive decline [35, 43–45]. In another amyloid PET study of 270 community-dwelling, cognitively normal elderly individuals followed for 1–5 years, steeper rates of increase for anxiety-concentration scores were associated with higher Pittsburgh Compound B PET-binding for amyloid [35]. These results persisted despite adjusting for depression history and intellectual background on a reading test, consistent with increasing anxiety with increasing Aβ burden over time [35]. In an autopsy study, postmortem interviews of informants for a cohort to 455 cases revealed that Braak I/II pathology (neurofibrillary tangles in transentorhinal/entorhinal region), significantly increased the odds of having anxiety, agitation, appetite changes, depression, and sleep disturbances, compared to controls, but there was no increased odds for anxiety with Aβ pathology or with worsening Braak stages [60]. Together, these findings suggest that anxiety is associated with early neurofibrillary tangle pathology in the entorhinal region in the presence of minimal cortical pathology [60].

POTENTIAL MECHANISMS FOR ANXIETY IN AD

There are several possible neurobiological reasons for an association of anxiety with AD (see Fig. 1). First, anxiety in mild AD may result from a widening attentional refocusing to (potentially threatening) socioemotional stimuli from decreased sensorimotor gating of environmental stimuli, a process suggested by a failure to inhibit an acoustic startle response with a preceding softer noise (“prepulse inhibition”) [61]. AD pathology in the entorhinal cortex may lead to decreased sensorimotor gating with larger initial orienting responses than normal, indicating enhanced perceptual processing of significant environmental stimuli [47, 62]. Second, in MCI and AD, early neurodegeneration in right mesial temporal lobes, with entorhinal involvement and relatively preserved amygdala, may lead to amygdalar hyperactivity and heightened emotional contagion [9, 47]. Emotional contagion is a primitive, rapid, and automatic synchronization of emotional and physiological states with another person [9, 63]. Third, anxiety may be secondary to a release of emotion generating structures in the salience network (SN) (an anterior insula-anterior cingulate predominant network). Increased SN activity results in increased visceromotor responsivity and emotional upregulation [9]. Finally, anxiety may be related to the presence of comorbid neuropathology, such as vascular changes or the presence of Lewy bodies. Anxiety is a common and early manifestation in dementia with Lewy bodies, and Lewy bodies are a frequent comorbidity of AD neuropathology [64–66].

Fig. 1

Potential mechanisms for anxiety in Alzheimer’s disease.

Beyond potential neurobiological explanations, there are possible psychosocial reasons for an association of anxiety with AD. Among patients with sufficient insight, the presence of anxiety could reflect a psychological reaction to their cognitive impairments early in the course of their disease. This anxiety is worse with caregiver separation and observing their performance on neurocognitive testing [14], and it is facilitated if there is preservation of right frontal and anterior cingulate regions involved in self-criticism [67]. In this last case, decreasing the threat posed by psychological symptoms may be one avenue for possibly delaying the onset of dementia due to AD [26]. As dementia progresses, there is further anxiety from the accumulation of cognitive and associated functional impairments and the inability to cope with environmental stressors [68, 69]. Importantly, AD patients have “unmet needs”, such as physical discomforts and socioemotional difficulties, which they cannot effectively communicate and may go unrecognized [69–71]. One model of behavioral symptoms in dementia stresses the progressive inability to handle stress from discomforts or difficulties [69, 70]. Patients with advanced AD may even learn to use disruptive behaviors, such as shouting or aggression, in order to gain attention to themselves and their discomforts or difficulties [71].

MANAGEMENT AND TREATMENT

The treatment of anxiety in AD and dementia usually consists of a combination of reassurance and support associated with limited use of pharmacotherapy. Removing precipitating or anxiety-producing triggers, responding to potential unmet needs, and maintaining a calm environment and steady routine can be most effective in managing anxiety and resultant agitation in AD. Treating anxiety includes managing intercurrent factors and comorbid conditions such as medication side-effects, sleep disturbances, and intercurrent medical conditions. Additional non-pharmacological techniques, such as visual arts, music, exercise programs, and aromatherapy should be considered [70, 71], and cognitive intervention therapy such as cognitive rehabilitation may be especially helpful for alleviating anxiety among those with MCI or mild dementia [69]. If behavioral or environmental intervention is insufficient, short-term use of benzodiazepines or the initiation of a selective serotonin reuptake inhibitor, are the drugs of choice. Low dose trazodone, particularly at bedtime, is an alternative when poor sleep or nocturnal agitation are factors. There can be psychoactive effects of the dementia medications, with acetylcholinesterase inhibitors occasionally worsening anxiety in some patients and memantine producing anxiety in others. Finally, if anxiety is severe and associated with agitation or physical aggression, clinicians may need to administer an atypical antipsychotic, despite the presence of a black-box warning label of increased morbidity and mortality with antipsychotic use in dementia.

CONCLUSIONS

AD manifests as a cognitive disorder; however, NPS are equally a part of the disease. Much literature has explored the apathy and depression associated with AD, but relatively less is known regarding anxiety, which is present in about 40%of AD patients. Anxiety often occurs early in the course of AD, especially among patients with MCI, mild dementia, or early-onset forms of the disease, and can promote progression and conversion from MCI to dementia. Anxiety is associated with positive amyloid scans and with mesial temporal changes in the entorhinal region, including atrophy, hypometabolism, and the presence of neurofibrillary tangles. The proposed mechanisms for anxiety in AD range from the neurobiological to the psychosocial and include contributions from cognitive impairments and environmental stressors. The management strategies for anxiety in patients with AD are important as anxiety can worsen cognitive deficits. Interventions involves psychological support, behavioral management, environmental changes, and, if necessary, the careful use of psychoactive medications.

CONFLICT OF INTEREST

The author has no conflict of interest to report.